Navigation Links
Micropharma Convenes Expert Roundtable on New Role for Probiotics in Cardiovascular Disease in time for National Cholesterol Education Month
Date:9/5/2012

MONTREAL, Sept. 5, 2012 /PRNewswire/ -- In advance of September's National Cholesterol Education Month, a roundtable of leading global experts in heart health, probiotics and nutrition convened in Chicago to discuss the development of a new scientific review paper looking at a new role for probiotics in cardiovascular disease.

The August 23 roundtable participants included:

  • Richard J. Deckelbaum, MD, CM, FRCPC, Robert R. Williams Professor of Nutrition, Professor of Pediatrics, Professor of Epidemiology, Director, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University Medical Center, New York
  • Mark L. Dreher, PhD, Nutrition Science Solutions
  • Jacques Genest, MD FRCP(C), Professor, Faculty of Medicine, McGill University; Novartis Chair in Medicine, McGill University; Scientific Director, Center for Innovative Medicine, McGill University Health Center/Royal Victoria Hospital, Montreal
  • Penny M. Kris-Etherton, PhD, RD; Distinguished Professor of Nutrition, Department of Nutritional Sciences, Penn State University, Pennsylvania
  • Mitchell Lawrence Jones, MD, PhD, CSO, Co-Founder, Micropharma, Montreal
  • Volker Mai, PhD, Associate Professor, Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Florida
  • Christopher John Martoni, PhD, Research Scientist, Micropharma, Montreal
  • Mary Ellen Sanders, PhD, Consultant, Dairy & Food Culture Technologies, Colorado

The roundtable was supported by Micropharma Limited.

Presentation at American Heart Association Scientific Sessions

Dr. Mitchell Jones, Micropharma chief scientific officer and co-founder, will present new clinical results about Cardioviva™ (Lactobacillus reuteri NCIMB 30242) at an oral presentation entitled "Probiotics for Heart Health:  Next Generation of Adjunct Therapies for Lipid Management," at the American Heart Association (AHA) Scientific Sessions on Nov. 5, 2012, in Los Angeles.

The association expects more than 20,000 scientists and healthcare professionals from more than 110 countries to attend the Scientific Sessions. It is the largest gathering devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases.  Results of the research will be available following the presentation.

About Micropharma Limited

Micropharma Limited, headquartered in Montreal, Quebec, is bringing a new approach to the development of over-the-counter healthcare products, medical foods, and biotherapeutics.  Micropharma applies a pathophysiological driven method to developing probiotic and enzyme therapies by focusing first on the health concern and then developing the effective products to support heath in that condition.  For more information, visit http://www.micropharma.net.


'/>"/>
SOURCE Micropharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
2. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
3. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
4. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
5. Renowned Operations and Supply Chain Expert Dr. David Simchi-Levi Joins OPS Rules
6. Mining cleanup benefits from Texas A&M expertise
7. Maths experts question key ecological theory
8. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
9. Fusion presents low proliferation risk, experts conclude
10. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
11. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):